Organigram Announces Record Q3 Financial Results

Published: July 30, 2018

Organigram Announces Record Q3 Financial Results

Organigram Holdings Inc., the parent company of Organigram Inc., a leading licensed producer of medical marijuana based in Moncton, New Brunswick, announced its financial results for the three and nine-months ended May 31, 2018.

Operational Highlights

  • Organigram began harvesting from its Phase 2 expansion facility (23 grow rooms) on April 20, 2018 bringing its target production of dried flower equivalent to 22,000 kg/annum;
  • In May the Company launched its adult recreational brand strategy which included house brands such as The Edison Cannabis CompanyANKR Organics and Trailer Park Buds;
  • In May Organigram received a “License for Controlled Drugs and Substances” from Health Canada making the Company a Licensed Dealer;
  • In May the Company received its “Permit to Export Cannabis” license which allowed Organigram the ability to make its first international medical shipment to Australia (completed in July);
  • Shortly after quarter-end the Company began use of its Phase 3 expansion filling six of the 16 grow rooms with the remaining rooms filled in June and July bringing its target production of dried flower equivalent to 36,000 kg/annum; and
  • Announced strategic investments in: Hyasynth Biologicals, Alpha-Cannabis Germany, and Eviana (see previous press releases for more details) which all are expected to close in the calendar third quarter.

Financial Highlights

  • Record net sales for both the three-months and nine-months ended May 31, 2018 of $3.7 million and $10.1 millionrespectively vs. $1.9 million and $3.6 million respectively for 2017;
  • Record sale volume of cannabis oil for the three-months ended May 31, 2018 (768,400 milliliters) up 39% from Q2/18 (552,250) and up 452% from Q3/17 (139,200 milliliters);
  • Record sales volume of dried flower (303,428 grams) for the three-months ended up 28% from Q2/18 (237,650 grams) and up 55% from Q3/17 (196,129 grams);
  • Record yields per plant in the quarter ended May 31, 2018 (see MD&A for further details);
  • Cost of cultivation per gram of dried flower harvested of $0.80 per gram “all-in” (direct labour and materials, allocated overhead and depreciation) and $0.58/gram excluding depreciation. Note that cost of cultivation is a non-GAAP measure used by management internally and does not include indirect production, packaging or shipping costs (see financial statements and MD&A for further details);
  • Registered medical patients climbed to a record 15,316 by the end of Q3 up 18% since Q2 (12,957);
  • Impairment of goodwill on its 2017 acquisition of Trauma Healing Centres in the amount of $1.2 million related to “right sizing” of the business opportunity;
  • Net interest expense of $3.7 million for the quarter primarily attributable to the interest expense on $115 million of convertible debentures issued on January 31, 2018; and
  • Net income of $2.8 million, an increase of 162% compared to $1.1 million in Q2-2018 and a loss of $2.3 million in Q3-2017.

Summary of Financial Results

Three-months ended

May 31

Inc.

(Decr.)

Nine-months ended

May 31

Inc

(Decr.)

(in $000 except EPS)

2018

2017

2018

2017

Gross sales

$ 3,705

$1,917

93%

$ 9,612

$ 5,593

72%

Sales recovery (return)

$ 21

$-

n/m1

$ 490

$(2,026)

n/m

Net sales2

$ 3,726

$1,917

94%

$ 10,102

$3,567

183%

Cost of sales (incl. indirect production)

$ 1,671

$2,097

-20%

$ 5,012

$5,905

-15%

Gross margin (excluding FV adjustment)

$ 2,055

$(180)

      n/m

$5,090

$ (2,338)

n/m

FV adjust. on bio assets and inventories

$ 10,066

$(578)

      n/m

$ 15,172

$ (1,634)

n/m

Gross margin

$ 12,121

$(758)

      n/m

$ 20,262

$ (3,972)

n/m

General and admin

$1,556

$ 790

97%

$ 4,743

$2,245

111%

Sales and marketing

$1,754

$691

154%

$ 4,033

$2,063

95%

Share-based compensation (non-cash)

$1,156

$222

421%

$ 3,056

$787

288%

Impairment of goodwill

$1,156

$   –

n/m

$ 1,156

$ –

n/m

Net financing costs (income) 3

$3,679

$ (115)

n/m

$4,778

$ (211)

n/m

Net income (loss)

$ 2,820

$(2,346)

n/m

$ 2,496

$(8,856)

%

EPS (basic)

$ 0.023

$(0.023)

n/m

$ 0.021

$ (0.093)

n/m

EPS (diluted)

$0.021

$(0.023)

n/m

$ 0.019

$ (0.093)

n/m

Sales volume of:

Dried cannabis flower (gr)

303,428

196,129

55%

736,153

598,060

23%

Cannabis oil sold (ml)

768,400

189,600

305%

1,739,250

406,000

328%

1 Not meaningful

Net sales consist of gross sales and sales recovery (return) and includes dried flower and cannabis oil sales, sales of accessories and revenues from the Company’s wholly-owned subsidiary Trauma Healing Center.

3 Net financing costs consist of financing costs less any investment income earned.

Balance Sheet Highlights

At the end of the third-quarter 2018 the Company reported:

  • $156 million in cash and short-term investments (up from $34 million at the August 31, 2017 year-end);
  • $26.9 million in combined biological assets and inventories (up from $5.4 million at year-end);
  • $83 million in property, plant and equipment (up from $45 million at year-end);
  • $9 million in current liabilities (up from $6 million at year-end);
  • $98 million in long-term debt and convertible debentures (up from $3 million at year-end);
  • 124.6 million outstanding shares (103.5 million at year-end); and
  • 140.5 million fully-diluted shares (114.2 million at year-end) – including 7.8 million options (6.3 million at year-end), 8.1 million warrants (4.3 million at year-end), and 21.2 million shares (–Nil at year-end) if the convertible debentures are converted at their conversion price of $5.42.

Outlook

  • Phase 4a (26 grow rooms) and 4b (27 grow rooms) construction expansions began in Q4 including a substantially complete 40-megawatt (peak capacity) substation worth $4 million – total cost of Phases 4a and 4b (including the $4 million spent on the substation) estimated to be $70 million bringing target production capacity to 89,000 kg/annum;
  • Phase 4c (24 grow rooms) which has an estimated cost of $40 million would bring target production capacity to 113,000 – construction scheduled to begin in January 2019;
  • Organigram expects to close its previously announced investments by the end of the quarter and is looking to augment its domestic and global capabilities with further investments and/or acquisitions; and
  • Company is confident it will be able to announce further provincial agreements in the adult recreational market in the current quarter.

Recent News

View All News Items

Latest Article

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

At any step in the cannabis supply chain, your labeling system should allow for full control and traceability, from seed to sale. Implementing lean principles and labeling best practices across the cannabis supply chain can help you streamline your seed-to-sale labeling process and help you gain control.

Click below to read the full blog and learn how to reduce waste, cut costs, and gain efficiency with cannabis labeling: https://bit.ly/2KwZ5IQ

Read Article